Type I Interferon Receptors: Biochemistry and Biological Functions

Weerd, Nicole A. de; Samarajiwa, Shamith A.; Hertzog, Paul J.

doi:10.1074/jbc.r700006200

Cited by 355 publications

(274 citation statements)

References 57 publications

Supporting

Mentioning

258

Contrasting

Unclassified

Order By: Relevance

“…Both type I and type II IFNs exert their actions through cognate receptor complexes, IFNAR and IFNGR, respectively, present on cell surface membranes. 9,10 In addition, novel interleukin 10-related cytokines, now known as type III IFN or IFN-l, display activities and functions much similar to those of type I IFNs, although they signal through different receptor complexes. The most important and best studied among the type I IFNs is IFN-a.…”

Section: The Ifn Familymentioning

confidence: 99%

Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms

2008

View full text Add to dashboard Cite

Interferon (IFN) was the first cytokine discovered 50 years ago, with a wide range of biological properties, including immunomodulatory, proapoptotic and antiangiogenic activities, that rapidly raised interest in its therapeutic use in malignancies. IFN-receptor characterization was also pivotal in the discovery of the JAK/STAT signaling pathway. Among the large IFN family, mainly one of the type I IFN, IFN-a2, is used in therapy. Many clinical trials have shown remarkable efficacy of IFN-a in bcr-abl-negative myeloproliferative neoplasms (MPNs), especially polycythemia vera (PV), and essential thrombocythemia (ET). IFN-a induces about 80% of hematological responses in those diseases and is able to reduce splenomegaly, as well as relieve pruritus and other constitutional symptoms. Yet its use was limited by toxicity, leading to early treatment discontinuation in about 20% of the patients. However, its lack of leukemogenic potential and its possible use during pregnancy have already made IFN-a the drug of choice for younger MPN patients. In addition, several studies have shown a probably selective effect of IFN-a on PV and ET clones, as shown by cytogenetic remissions, reversions to polyclonal hematopoiesis, and more recently by induction of JAK2V617F complete molecular remissions in PV which may widen the indications of IFN-a in JAK2-mutated MPN.

show abstract

Section: The Ifn Familymentioning

confidence: 99%

Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms

2008

View full text Add to dashboard Cite

show abstract

“…[10][11][12] How does IFNa kill cancer cells or stop viral replication? By four principle pathways: (1) enhancing intracellular apoptotsis forces in infected/cancer cells, (2) by enhancing non-infected lymphocytes' responses to immune stimulation, (3) by enhancing various and multiple anti-viral replication functions, (4) by retarding protein synthesis.…”

Section: Ifnamentioning

confidence: 99%

“…10,11 IFNa and IFNb are the main Type I interferons studied to date. Type II interferons, primarily IFNgamma, signal through Type II receptors.…”

Section: Ifnamentioning

confidence: 99%

Potential for all-trans retinoic acid [tretinoin] to enhance interferon-alpha treatment response in chronic myelogenous leukemia, melanoma, myeloma, and renal cell carcinoma

Kast¹

2008

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…Both the IFN−αs and IFN−βs bind a single heterodimeric receptor (IFNAR composed of both IFNAR1 and IFNAR2 subunits), expressed by almost all cells in human and mouse [20][21][22][23]. Furthermore, levels of IFNAR2 in the liver have been shown to be a predictive biomarker of response to IFN treatment in chronic hepatitis C patients [24].…”

Section: Ifn Signalingmentioning

confidence: 99%

Interferons as Biomarkers and Effectors: Lessons Learned from Animal Models

2012

View full text Add to dashboard Cite

Interferons (IFNs) comprise type I, II and III families with multiple subtypes. Via transcription of IFNstimulated genes (ISGs), IFNs can exert multiple biological effects on the cell. In infectious and chronic inflammatory diseases, the IFNs and their ISG sets can be potentially utilized as biomarkers of disease outcome. Animal models allow investigations into disease pathogenesis and gene knockout models have proved cause and effect relationships of molecules related to the IFN response. Sets of IFN subtypes and their ISG products provide immunological signature patterns for different viral and other diseases. In this article, we give an overview of IFNs in several virus infection models and autoimmune diseases of medical relevance. Lessons learned from animal models inform us of IFN system parameters as indicators of disease outcome and whether clinical research is warranted. Moreover, validated IFN biomarkers for prognosis enhance our understanding of therapeutic and vaccine development.

show abstract

Type I Interferon Receptors: Biochemistry and Biological Functions

Cited by 355 publications

References 57 publications

Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms

Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms

Potential for all-trans retinoic acid [tretinoin] to enhance interferon-alpha treatment response in chronic myelogenous leukemia, melanoma, myeloma, and renal cell carcinoma

Interferons as Biomarkers and Effectors: Lessons Learned from Animal Models

Contact Info

Product

Resources

About